Comparison of the antigenemia assay and screening bronchoscopy for detection of cytomegalovirus infection after bone marrow transplantation

The usefulness of a diagnostic method combining high-resolution CT findings and serum markers for cytomegalovirus pneumonia and pneumocystis pneumonia in non-AIDS patients

BACKGROUND

The combination of high-resolution computed tomography (HRCT) findings and serum markers would be of great value in diagnosing cytomegalovirus pneumonia (CMVP) and pneumocystis pneumonia (PCP) considering low invasiveness.

PURPOSE

To compare the HRCT findings of CMVP and PCP and to evaluate the differences in HRCT findings between patients diagnosed based on pathologic evidence and serum markers.

MATERIAL AND METHODS

Two radiologists retrospectively evaluated the HRCT findings of 21 patients with CMVP and 70 patients with PCP. Eight patients with CMVP and 32 patients with PCP were diagnosed based on pathologic evidence ("Path" group), while 13 patients with CMVP and 38 patients with PCP were diagnosed based on serum markers (CMV antigenemia, β-D-glucan) ("Serum-Marker" group). A total of 19 CT morphological criteria were evaluated, and the significance of the differences between the two diseases and between the "Path" and "Serum-Marker" groups with respect to each disease was calculated.

RESULTS

The presence of small nodules, the tree-in-bud pattern, and the halo sign was found more frequently in the CMVP group. Extensive ground-glass attenuation (GGA), a mosaic pattern, and a diffuse distribution were observed more frequently in the PCP group. There were significant differences between the "Path" and "Serum-Marker" groups in average extent of consolidation and distribution of consolidation in PCP, and the distribution of GGA in CMVP, respectively.

CONCLUSION

The combined use of HRCT findings and serum markers is useful for the diagnosis of CMVP and PCP in non-AIDS patients. The typical HRCT findings for the differential diagnosis included extensive GGA with mosaic pattern in PCP and nodules, nodules with or without the tree-in-bud pattern, and the halo sign in CMVP.

Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus

The best-known function of the serine protease tissue-type plasminogen activator (tPA) is as a thrombolytic enzyme. However, it is also found in structures of the brain that are highly vulnerable to hypoxia-induced cell death, where its association with neuronal survival is poorly understood. Here, we have demonstrated that hippocampal areas of the mouse brain lacking tPA activity are more vulnerable to neuronal death following an ischemic insult. We found that sublethal hypoxia, which elicits tolerance to subsequent lethal hypoxic/ischemic injury in a natural process known as ischemic preconditioning (IPC), induced a rapid release of neuronal tPA. Treatment of hippocampal neurons with tPA induced tolerance against a lethal hypoxic insult applied either immediately following insult (early IPC) or 24 hours later (delayed IPC). tPA-induced early IPC was independent of the proteolytic activity of tPA and required the engagement of a member of the LDL receptor family. In contrast, tPA-induced delayed IPC required the proteolytic activity of tPA and was mediated by plasmin, the NMDA receptor, and PKB phosphorylation. We also found that IPC in vivo increased tPA activity in the cornu ammonis area 1 (CA1) layer and Akt phosphorylation in the hippocampus, as well as ischemic tolerance in wild-type but not tPA- or plasminogen-deficient mice. These data show that tPA can act as an endogenous neuroprotectant in the murine hippocampus.

Cytomegalovirus pneumonia after bone marrow transplantation: high resolution CT findings

Cytomegalovirus (CMV) pneumonia is one of the most common pulmonary complications after bone marrow transplantation (BMT). We describe the high resolution CT (HRCT) findings of 13 patients with CMV pneumonia diagnosed after allogenic BMT. The study included 13 consecutive patients who developed CMV pneumonia after BMT and who had HRCT of the chest performed within 24 h of the onset of symptoms. HRCT scans were reviewed by two radiologists who assessed pattern and distribution of findings. There were nine male and four female patients, ranging from 9 years to 56 years of age (mean age 33 years). BMT was performed for treatment of chronic myelogenous leukaemia (54%), severe aplastic anaemia (23%), acute myelogenous leukaemia (15%) and Fanconi's anaemia (8%). The time elapsed until diagnosis ranged from +18 days to +405 days (median of 54 days, mean +81.6 days). The predominant patterns of abnormality on HRCT scans were ground-glass opacities (69%), small centrilobular nodules (69%) and air-space opacities (54%). The abnormalities were distributed in the central and peripheral zones of the lungs in six cases, only in the periphery in four cases, and only in the central zone in three cases. In all cases the lung lesions were bilateral, and asymmetry was observed in seven cases. The authors conclude that the most common HRCT findings in patients with CMV pneumonia after BMT consist of bilateral asymmetric ground-glass, air-space opacities and small centrilobular nodules.